Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
British Journal of Clinical Pharmacology|August 8, 2009
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthmaPhilip J Lowe, Stacey Tannenbaum, Aurelie Gautier, et al.
The World Allergy Organization Journal|October 3, 2022
The rationale for development of ligelizumab in food allergyRobert A Wood, R Sharon Chinthrajah, Alexander Eggel, et al.
British Journal of Clinical Pharmacology|August 7, 2024
Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European UnionRui Zhu, Rik Schoemaker, Aurelie Gautier, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 23, 2025
Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous UrticariaAndrzej Bienczak, Aurelie Gautier, Eva Hua, et al.
Clinical & Translational Immunology|March 22, 2021
Ligelizumab treatment for severe asthma: learnings from the clinical development programmeJordis Trischler, Ivan Bottoli, Reinhold Janocha, et al.
Pulmonary Pharmacology & Therapeutics|September 30, 2021
Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polypsRui Zhu, Ryan Owen, Justin Wilkins, et al.
Allergy|January 20, 2026
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut AllergyPhilippe Bégin, Motohiro Ebisawa, Antonella Muraro, et al.
Pageof 1